

SADS

President & Medical Director

G. Michael Vincent, M.D. Salt Lake City, UT

Board of Trustees

G. Michael Vincent, M.D.
Salt Lake City, UT
David E. Salisbury
Salt Lake City, UT
Katherine W. Timothy
Salt Lake City, UT
Ralph W. Hardy, Jr.
Washington, DC
Richard M. Cagen
Salt Lake City, UT

International Affiliates

Australian SADS
Julie Foley
Victoria, Australia
The Canadian SADS
Foundation
Parn Husband
Ontano, Canada
SADS UK
Anne Jolly
Essex, England

Scientific Advisors


Peter J. Schwartz, M.D. Milan, Italy Charles Antzelevitch, Ph.D. Utica, NY Arthur Garson, Jr., M.D. Durham, NO Thomas S. Klitzner, M.D. Los Angeles, CA Dan M. Roden, M.D. Nashville, TN Jeffrey A. Towbin, M.D. Houston, TX Victoria L. Vetter, M.D. Philadelphia, PA Raymond L. Woosley, M.D., Ph.D. Washington, DC

National Advisors

Denise Falzon
Orchard Lake, MI
Shirley Gaster
Philadelphia, PA
Sally & Bill Layton
Colerado Springs, CO
Darrell & Connie Ogden
Salt Lake City, UT
Kathy Price
Dellas, TX
Richard Stafford
Phoenix, AZ

Staff

Lynne Godfrey Christie Machan Robin Brown 17 May 01



The Sudden Arrhythmia Death Syndromes (SADS) Foundation

508 E. South Temple, Suite 20, Salt Lake City, Utah 84102 800 STOP SAD or 801-531-0937; Fax: 801-531-0945

THE LONG QT SYNDROME AND PREGNANCY - A.J. Morris MD, University of Rochester NY

The Long QT Syndrome (LQTS) is a genetically transmitted disorder that affects the electrical activity of the heart. Individuals affected with this condition may lead entirely normal lives, but others are at increased risk of developing serious heart rhythm disorders that may be manifest as passing-out spells (syncope) and/or sudden death. Fortunately, very good treatments are now available to stabilise the electrical circuits of the heart and to prevent dangerous changes in the heart beat.

For the past 15 years, the Rochester group, in conjunction with our medical colleagues at other academic institutions in the United States and Europe, have maintained an International LQTS Registry to better understand the natural history and clinical course of patients with this disorder in order to develop more effective preventive therapy. We have recently used this Registry that involves over 700 families with LQTS and more than 3,000 affected family members, to evaluate the effect of pregnancy on the occurrence of cardiac events in women with the hereditary Long QT Syndrome.

This pregnancy study was a retrospective analysis of 216 women with documented LQTS who had one or more pregnancies. The study population consisted of 111 probands (the first member of a family to be identified with LQTS, usually because of symptoms such as syncope) and 105 affected family members who generally had not experienced any symptoms. The incidence of heart events including syncope, aborted cardiac arrest, and sudden death was compared during equal 9 month pre-pregnancy, pregnancy, and post-pregnancy intervals in the probands and the affected family members.

What did we find. First, the 9 month interval during pregnancy and the delivery itself were not associated with an increased occurrence of heart events in any of the LQTS women. Secondly the 9 month period after pregnancy (the post-partum interval) was associated with an increased number of serious heart events in some women, especially the proband women who had experienced heart related symptoms (syncope) a year or more before the pregnancy. Thirdly, treatment with beta-blocker medication, standard therapy for symptomatic patients with LQTS, was associated with a significant reduction in the risk of serious heart events during and after the pregnancy. That is, LQTS women receiving beta-blocker medication did much better than those who did not receive this medication. Fourthly beta-blocker therapy had no adverse effects on the pregnancy or the foetus.

What can we conclude from this study? It appears that the physical and emotional stress during the postpartum period after pregnancy may be a factor in triggering heart rhythm disorders in some vulnerable
women with LQTS. Certainly, the responsibilities of caring for a newborn, the interrupted sleeping
schedule, the changing hormonal environment in the body, and fatigue, common features after
pregnancy, may all be contributing factors to increase the occurrence of heart events during the postpartum interval. Every effort should be made to reduce the post-partum stress in the patients. Patients
with LQTS who have had prior heart events should be prophylactically treated with beta-blocker
medication, and this therapy is especially important in relationship to the pregnancy and should be
continued during and after the pregnancy. Women with LQTS who are contemplating pregnancy should
be seen in consultation by a cardiologist, and followed by the cardiologist during the course of the
pregnancy, and afterwards.

We now have a better understanding that in LQTS women the risk of heart events increases in the 9 month interval after pregnancy. Furthermore, effective treatment is available in the form of betablockers to make pregnancy and the post-partum period safer. Clearly, an ounce of prevention is worth a pound of cure.

The Ashley Jolly Sad Trust and Sads UK do not have a medical background. We endeavour to give the best information as supplied to us from research carried out and contact with experts. We cannot guarantee any of the information given but we confirm that this has been given in good faith and true compassion. Neither the Charitable Trust nor the individual trustees thereof will be liable to any person who acts or omits to act in reliance upon it.

Registered Charity No. 1079726
Affiliated to SADS UK, America, Australia & Canada
For more information please contact: Anne Jolly: 01277 230642
e-mail: info@sadsuk.org www.sadsuk.org